Posted by Michael Wonder on 14 Sep 2022
Minoryx‘s marketing authorisation application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked adrenoleukodystrophy
14 September 2022 - 4, 2022 - Minoryx Therapeutics today announces that it has filed a marketing authorisation application for its lead candidate leriglitazone to the EMA for the treatment of adult male patients with X-linked adrenoleukodystrophy.
Minoryx’s leriglitazone is a novel, brain penetrant and selective PPAR gamma agonist.
